Polyinosinic-polycytidylic acid (sodium)

42424-50-0

1000

H₂O : 10 mg/mL (ultrasonic; warming)

Apoptosis; Immunology/Inflammation

Polyinosinic-polycytidylic acid sodium (Poly(I:C) sodium) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid sodium can directly trigger cancer cells to undergo apoptosis^[1][2]. IC50 & Target: TLR3^[2], RIG-I^[2], MDA5^[2], apoptosis^[2] In Vitro: Polyinosinic-polycytidylic acid (20 ng/mL; 24 hours; WM793, WM278, WM239A, WM9 and 1205Lu cells) treatment strongly reduces viability from 100% in controls to 20%-50% within 24 hours^[1].
Polyinosinic-polycytidylic acid (200 ng/mL; 24 hours; 1205Lu cells) treatment induces apoptosis in 1205Lu cells^[1].
Polyinosinic-polycytidylic acid (3 ng/mL; 24 hours; 1205Lu cells) treatment induces IFN-beta expression in melanoma cells. Silencing of RIG-I and MDA-5 confirmed that induction of IFN-beta by Polyinosinic-polycytidylic acid required RIG-I and MDA-5, respectively, and that required IPS-1^[1].
Polyinosinic-polycytidylic acid (5 ng/mL; 24 hours; 1205Lu cells) treatment reveals active subunits of caspase-9 and caspase-8 in melanoma cells^[1].
Polyinosinic-polycytidylic acid sodium is prepared for injection by resuspending in sterile saline, heating to 50 C at a concentration of 2 mg/ml to ensure complete solubilisation and then allowing to cool naturally to room temperature to ensure proper annealing of double-stranded RNA. Poly I:C is stored at -20 C until use^[3].
In Vivo: Polyinosinic-polycytidylic acid treatment inhibits tumor growth in NOD/SCID immunodeficient mice injected with 1205Lu cells. The level of human DNA is 50% lower in mice treated with Polyinosinic-polycytidylic acid^[1].